Great Lakes Advisors LLC Has $102.90 Million Stake in Thermo Fisher Scientific Inc. $TMO

Key Points

• Great Lakes Advisors LLC increased its stake in Thermo Fisher Scientific by 2.2%, now holding 208,248 shares valued at approximately $102.9 million, which represents 0.9% of its total portfolio.
• Recent analyst activity shows that Scotiabank upgraded the stock from "sector perform" to "sector outperform," with a price target of $590, while the consensus price target among analysts is $589.38.
• Thermo Fisher Scientific reported an EPS of $5.36 for the last quarter, beating expectations, and has set future earnings guidance between $5.460 and $5.510 for Q3 2025.

Great Lakes Advisors LLC lifted its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 2.2% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 208,248 shares of the medical research company's stock after acquiring an additional 4,580 shares during the period. Thermo Fisher Scientific accounts for about 0.9% of Great Lakes Advisors LLC's holdings, making the stock its 28th biggest position. Great Lakes Advisors LLC owned approximately 0.06% of Thermo Fisher Scientific worth $102,897,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the business. Sciencast Management LP grew its position in shares of Thermo Fisher Scientific by 116.9% during the first quarter. Sciencast Management LP now owns 7,195 shares of the medical research company's stock worth $3,580,000 after acquiring an additional 3,878 shares during the last quarter. Voleon Capital Management LP purchased a new position in shares of Thermo Fisher Scientific during the first quarter worth approximately $3,923,000. Ashton Thomas Private Wealth LLC grew its position in shares of Thermo Fisher Scientific by 5.1% during the first quarter. Ashton Thomas Private Wealth LLC now owns 10,458 shares of the medical research company's stock worth $5,208,000 after acquiring an additional 508 shares during the last quarter. Kestra Investment Management LLC lifted its holdings in shares of Thermo Fisher Scientific by 72.0% during the first quarter. Kestra Investment Management LLC now owns 597 shares of the medical research company's stock worth $297,000 after purchasing an additional 250 shares during the period. Finally, Resources Management Corp CT ADV lifted its holdings in shares of Thermo Fisher Scientific by 20.7% during the first quarter. Resources Management Corp CT ADV now owns 4,223 shares of the medical research company's stock worth $2,101,000 after purchasing an additional 724 shares during the period. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages recently weighed in on TMO. Wall Street Zen downgraded Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Sunday. William Blair began coverage on Thermo Fisher Scientific in a report on Monday, August 18th. They set an "outperform" rating for the company. Hsbc Global Res downgraded Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 24th. UBS Group raised their target price on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a report on Thursday, July 24th. Finally, Barclays raised their price target on Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an "equal weight" rating in a research report on Thursday, July 24th. Sixteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat.com, Thermo Fisher Scientific currently has an average rating of "Moderate Buy" and a consensus price target of $589.38.

Insider Activity

In other news, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer owned 2,319 shares of the company's stock, valued at approximately $1,142,408.97. This trade represents a 14.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Gianluca Pettiti sold 400 shares of the business's stock in a transaction on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the sale, the executive vice president directly owned 22,367 shares in the company, valued at approximately $10,735,712.66. This represents a 1.76% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 30,066 shares of company stock valued at $14,182,963. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Down 1.1%

Thermo Fisher Scientific stock traded down $5.38 during midday trading on Wednesday, hitting $477.03. 1,442,085 shares of the company were exchanged, compared to its average volume of 1,608,466. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $623.77. The company's fifty day moving average price is $464.58 and its 200-day moving average price is $452.37. The company has a market cap of $180.13 billion, a PE ratio of 27.59, a price-to-earnings-growth ratio of 2.58 and a beta of 0.75.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business had revenue of $10.86 billion during the quarter, compared to the consensus estimate of $10.68 billion. During the same period in the previous year, the business earned $5.37 EPS. The business's quarterly revenue was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is presently 9.95%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.